Data processing: measuring – calibrating – or testing – Measurement system in a specific environment – Biological or biochemical
Reexamination Certificate
2007-04-17
2007-04-17
Clow, Lori A. (Department: 1631)
Data processing: measuring, calibrating, or testing
Measurement system in a specific environment
Biological or biochemical
C702S020000, C702S022000
Reexamination Certificate
active
09836477
ABSTRACT:
The present invention concerns methods for measuring drug resistance by correlating genotypic information with phenotypic profiles. In one embodiment, a method for interpreting genotypic information is described wherein a genetic code is generated from a patient sample, a list of mutations known or suspect to play a role in the development of resistance to one or more drugs is obtained from the generated genetic code, a genotype database is interrogated for previous samples with similar mutations relating to said one or more drugs, a phenotype for said sample is located in a phenotype database, the mean change in inhibition is determined based on all the examples located in said phenotype database, a distribution of sensitivities of one or more drugs suitable for treating a specific indication is determined.
REFERENCES:
patent: 5202259 (1993-04-01), Goff et al.
patent: 6087093 (2000-07-01), Lieven et al.
patent: 6221578 (2001-04-01), de Bethune et al.
patent: 6869759 (2005-03-01), Parkin et al.
patent: 0 203 200 (1990-01-01), None
patent: WO 94/16737 (1994-08-01), None
patent: WO 97/27480 (1997-07-01), None
patent: WO 99/40227 (1999-08-01), None
patent: WO 99/61658 (1999-12-01), None
patent: WO 99/67427 (1999-12-01), None
patent: WO 00/73511 (2000-12-01), None
patent: WO 00/78996 (2000-12-01), None
patent: WO 01/16860 (2001-03-01), None
patent: WO 01/57245 (2001-08-01), None
Harrigan et al. (AIDS (1999) vol. 13, No. 14, pp. 1863-187.
Ioannidis et al. (American Journal of Epidemiology (1998) vol. 147, No. 5, pp. 464-471.
Boden et al. (JAMA (1999) Sep., vol. 282, No. 12, pp. 1135-1141).
Virologic HIV Assays:Review of Report Forms).
Hertogs et al (Antimicro. Agents and Chemo. (Mar. 2000) vol. 44, pp. 568-573).
Harrigan et al., “Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting”, AIDS, 13, pp. 1863-1871, (1999).
Hertogs et al., “Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis”, AIDS, 13(14), Poster Abstracts OP3.4, p. 11.
Vandamme et al., “Managing Resistance to Anti-HIV Drugs—An important Consideration for Effective Disease Management”, DRUGS 1999, 57(3), pp. 337-361, (1999).
Walter et al., “Rapid, phenotypic HIV-1 drugs sensitivity assay for protease and reverse transcriptase inhibitors”, Journal of Clinical Virology, 13, pp. 71-80, (1999).
Wegner et al., “Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel”, AIDS, 14, pp. 1009-1015, (2000).
Beroud, et al., “UMD (Universal Mutation Database): A Generic Software to Build and Analyze Locus-Specific Databases,”Human Mutation, 2000, 15(1), 86-94.
Cohen, C. et al. 3 Abstracts, “Phenotypic Resistance Testing Significantly Improves Response to Therapy: A Randomized Trial,” “Exploration of HIV-Infection as a Risk Factor for Symptomatic Plasma Cell Endometritis,” “Forty-Eight Week Analysis of Patients Receiving T-20 as a Component of Multi-Drug Salvage Therapy,”XIII International AIDS Conference, 2000.
D'Aquila, R.T., “HIV-1 Chemotherapy and Drug Resistance,”Clinical Diagnostic Virology, 1995, 3, 299-316.
De Gruttola, V. et al., “The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy; Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan,”Antiviral Therapy, 2000, 5, 41-48.
De Leon, et al., “Clinical Features and Genotype-Phenotype Correlations in 41 Italian Families with Adenmatosis Coli,”Italian Journal of Gastoenterology and Hepatology, 1990, 31(1), 850-860.
Eastman, P.S., “Comparison of Selective Polymerase Chain Reaction Primers and Differential Probe Hybridization of Polymerase Chain Reaction Products for Determination of Relative Amounts of Codon 215 Mutant and Wild-Type HIV-1 Populations,”Journal of Acquired Immune Deficiency Syndrome and Human Retroviology, 1995, 9, 264-273.
Edman, P., “Sequence Determination,”Mol. Biol. Biochem. Biophys, 1970, 8, 211-255.
Estellar, M. et al., “Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating Agents,”New England Journal of Medicine, 2000, 343, 19, 1350-1354.
Fodor, S.P. et al., “Multiplexed Biochemical Assays with Biological Chips,”Nature, 1993, 364, 555-556.
Graber, J. et al., “Differential Sequencing with Mass Spectrometry,”Genetic Analysis: Biomolecular Engineering, 1999, 14, 215-219.
Hertogs, K. et al., “A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs,”Antimicrobial Agents Chemotherapy, 1998, 42(2), 269-276.
Hirsh, et al., “Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection,”The Journal of American Medical Association, May 2000, 283(18), 2417-2426.
Japour, A.J. et al., “Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 Isolates”, “The RV-43 Study Group & The ACTG Virology Committee Resistance Working Group,”Antimicrobial Agents Chemotherapy, 1993, 37, 1095-1101.
Jeanpierre, et al., “Software and Database for the Analysis of Mutation in the Human WT1 Gene,”Nucleic Acids Research, 1998, 26(1), 271-274.
Kellam, P. et al., “Recombinant Virus Assay: A Rapid, Phenotypic Assay for Assessment of Drug Susceptibility of Human Immunodeficiency Virus Type 1 Isolates,”Antimicrobial Agents and Chemotherapy, 1994, 38, 23-30.
King, P.J. et al., “Resistance to the Anti-Human Immunodeficiency Virus Type 1 Compound L-Chicoric Acid Results from a Single Mutation at Amino Acid 140 of Integrase,”Journal of Virology, 1998, 72(10), 8420-8424.
Larder, B.A. et al., “Zidovudine Resistance Predicted by Direct Detection of Mutations in DNA from HIV-Infected Lymphocytes,”AIDS, 1991, 5, 137-144.
Larder, et al., “A Complete Survey, In Over 1,500 Clinical HIV-1 Isolates, of Phenotypic and Genotypic Protease Inhibitor Resistance Profiles (Including Gag Cleavage Site Sequences) and Their Relation to Therapy History,”AIDS, 1998, 12(4), S11, OP3.5.
Larder, B.A. et al., “Use of Neural Networks to Define the Genetic Basis of HIV-1 resistance to d4T,”Fifth International Conference on Drug Therapy in HIV Infection, Glasgow, 2000, 14(4), PL 9.5.
Laurent-Puig Pierre, et al., “APC Gene: Database of Germline and Somatic Mutations in Human Tumors and Cell Lines,”Nucleic Acids Research, 1998, 26(1), 269-270.
Pauwels, R. et al., “Comprehensive HIV Drug Resistance Monitoring Using Rapid, High-Throughput Phenotypic and Genotypic Assays With Correlative Data Analysis,”2ndInternational Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, Jun. 24-27, 1998, Abstract 51, 35-36.
Pauwels, R. et al., “Correlation between Genotypic and Phenotypic Resistance Data in AVANTI,”Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997, 37, 263-264 I-112.
Peipkorn, M., “Genetic Basis of Susceptibility to Melanoma,”Journal of the American Academy of Dermatoloty, 1994, 31(6), 1022-1039 (Abstract only).
Petropoulos, C.J. et al., “A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1,”Antimicrobial Agents Chemotherapy, 2000, 44(4), 920-928.
Petropoulos, C.J. et al., “Human Immunodeficiency Virus 1, Complete Genome,”Database Genebank NCBI, 2000, Accession nr. NC—001802, 11 pages.
Reinke, et al., “Natural Selection Results in Conservation
Bloor Stuart
Dehertogh Pascale Alfons Rosa
Hertogs Kurt
Larder Brendan
Mortier Rudy Jean Marc
Clow Lori A.
Ren Yunling
Virco N.V.
LandOfFree
Methods for measuring therapy resistance does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for measuring therapy resistance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for measuring therapy resistance will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3757421